Starling Oncology, Inc. (STLN)

Starling Oncology Revenue

Starling Oncology had revenue of $161.28M in the quarter ending June 30, 2026, with 34.62% growth. This brings the company's total for the last twelve months to $587.24M, up 38.38% year-over-year. In the year 2025, Starling Oncology had annual revenue of $502.73M with 27.79% growth. That makes Starling Oncology the 10,341st largest company in the world by revenue and 2,189th in the United States.

• Revenue (ttm): $587.24M
• Revenue Growth: +38.38%
• P/S Ratio: 1.15
• Revenue / Employee: $916,137
• Employees: 641
• Market Cap: 650.22M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Specialty Pharmacy 269.18M 53.5%
• Patient Services 228.99M 45.5%
• Clinical Trials & Other 4.56M 0.9%

Fiscal year ended Dec 31, 2025 See the full Starling Oncology breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	502.73M	109.32M	27.79%
Dec 31, 2024	393.41M	69.17M	21.33%
Dec 31, 2023	324.24M	71.76M	28.42%
Dec 31, 2022	252.48M	49.48M	24.37%
Dec 31, 2021	203.00M	15.49M	8.26%
Dec 31, 2020	187.52M	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Aug 6, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue segment data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Oct 27, 2026

Data Sources Report a data error